Clinical Trial Update: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Gavo-cel (TC-210), a mesothelin-targeted therapy, in patients with advanced mesothelin-expressing cancers. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• High-grade Ovarian Serous Adenocarcinoma
• Malignant Mesothelioma
• Malignant Pleural Mesothelioma
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• Gavo-cel (TC-210)

Snippet

Sponsor: TCR2 Therapeutics | Conditions: Mesothelioma, Mesothelioma, Malignant | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING